21 recruiting, 10 completed, 6 unknown, 3 terminated. 20 Phase 2, 8 Phase 1, 3 Phase 3, 2 Not applicable, 1 Phase 4.
Follow Immune Checkpoint Inhibitor: new trials by email Literature Review of Immune Checkpoint Inhibitor trials Research Report on Immune Checkpoint Inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial Ruxolitinib, Pembrolizumab - Carcinoma, Squamous Cell of Head and Neck HNSCC | Phase 2 | Not yet recruiting | University Hospital, Basel, Switzerland | 66 | 2026-11-01 | 2026-10-20 |
| NK Cells Plus ICI for SCLC Maintenance Allogeneic Natural Killer Cells, Immune Checkpoint Inhibitor - Small Cell Lung Cancer | Phase 2 | Recruiting | Tianjin First Central Hospital | 42 | 2026-08-01 | 2026-08-12 |
| Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting Becotatug vedotin (MRG003) - ESCC | Phase 2 | Recruiting | The First Affiliated Hospital of Bengbu Medical University | 38 | 2026-05-01 | 2026-10-23 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer Best Practice, Biopsy of Breast, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Washington | 22 | 2026-02-26 | 2026-05-19 |
| Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma Albumin-bound Paclitaxel, Immune Checkpoint Inhibitor, Anti-angiogenic drug - Gastric Cancer, Second-line Treatment | Recruiting | Fudan University | 250 | 2025-09-01 | 2026-02-05 | |
| Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors DT-7012, Immune checkpoint inhibitor - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Domain Therapeutics Australia Pty Ltd | 125 | 2025-06-25 | 2026-05-06 |
| Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Sintilimab, Short-course radiotherapy, Long-course concurrent chemoradiotherapy - Locally Advanced Rectal Cancer (LARC) | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 228 | 2025-06-01 | 2025-06-26 |
| Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma Stereotactic Body Radiotherapy (extracranial) concurrent with Immunotherapy, Immunotherapy alone - Melanoma Metastatic | Phase 2 | Recruiting | Melanoma Institute Australia | 129 | 2025-03-06 | 2026-05-07 |
| ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI Immune checkpoint inhibitor - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Peking Union Medical College Hospital | 27 | 2024-08-09 | 2024-11-07 |
| IC Plus Low-dose Radiation Plus Cadonilimab in LANPC Intensity Modulated Radiation Therapy, Chemotherapy, Immune checkpoint inhibitor - Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor | Phase 3 | Recruiting | Sun Yat-sen University | 380 | 2024-01-10 | 2026-05-11 |
| Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer Immunotherapy, Targeted therapy, Hyperthermia - Metastatic Castration-resistant Prostate Cancer (CRPC) | Phase 2 | Recruiting | Pengyuan Liu | 60 | 2024-01-01 | 2024-02-08 |
| Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer Immune checkpoint inhibitor, FOLFOX regimen - Locally Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 170 | 2023-11-01 | 2025-11-28 |
| Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies BDC-3042, Cemiplimab - Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma | Phase 1 | Terminated | Bolt Biotherapeutics, Inc. | 17 | 2023-10-11 | 2025-11-17 |
| Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer Immune checkpoint inhibitor - Non Small Cell Lung Cancer | Recruiting | Shanghai Chest Hospital | 250 | 2023-10-01 | 2024-12-12 | |
| A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial IMSA101, Immune Checkpoint Inhibitor - Solid Tumor, Adult | Phase 1 | Active not recruiting | ImmuneSensor Therapeutics Inc. | 2 | 2023-09-15 | 2024-11-18 |
| Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC Super-hyperfractionation Pulse Radiotherapy - Lung Cancer, Immune Checkpoint Inhibitor | Not applicable | Recruiting | Xinqiao Hospital of Chongqing | 40 | 2023-08-01 | 2025-07-14 |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies IMSA101, Immune checkpoint inhibitor, PULSAR - Oligoprogressive | Phase 2 | Terminated | ImmuneSensor Therapeutics Inc. | 16 | 2023-07-07 | 2026-05-15 |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC IMSA101, Immune checkpoint inhibitor, PULSAR - Oligometastatic Disease | Phase 2 | Terminated | ImmuneSensor Therapeutics Inc. | 6 | 2023-06-28 | 2025-10-20 |
| Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI CP-506, Carboplatin, Immune checkpoint inhibitor - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Recruiting | Maastricht University Medical Center | 126 | 2023-05-30 | 2025-10-07 |
Showing 20 of 44. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Melanoma (5) · Carcinoma, Hepatocellular (4) · Carcinoma, Renal Cell (4) · Head and Neck Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (3) · Colorectal Neoplasms (2) · Hyperthermia (2) · Lung Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Triple Negative Breast Neoplasms (2) · Arthritis (1) · Autoimmune Diseases (1)
ImmuneSensor Therapeutics Inc. (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Groupe Hospitalier Pitie-Salpetriere (2) · Hunan Cancer Hospital (2) · Peking University Cancer Hospital & Institute (2) · Pengyuan Liu (2) · Shanghai Chest Hospital (2) · Sun Yat-sen University (2) · Baylor College of Medicine (1) · Bolt Biotherapeutics, Inc. (1) · Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1) · Domain Therapeutics Australia Pty Ltd (1) · ETOP IBCSG Partners Foundation (1) · Erasmus Medical Center (1)
China (22) · United States (10) · Belgium (3) · France (3) · Netherlands (3) · Australia (2) · Italy (2) · Spain (2) · Switzerland (2) · Canada (1) · Germany (1) · Hong Kong (1) · Slovenia (1) · United Kingdom (1)
Patrick Widhelm (2) · Ajay Sheshadri (1) · Angela Hong (1) · Anna Brandt, PD Dr. (1) · Bianca Mostert, MD (1) · Chao Liu, PhD (1) · Chi Leung Chiang, Chiang (1) · Chong Zhao, MD, PhD (1) · Els Wauters, MD, PhD (1) · Francesco Zaja, Professor (1) · Henk Verheul, MD, PhD (1) · Irene Brana, MD, PhD (1) · Jennifer Specht, MD (1) · Jian Fang (1)
PMID 18457330, PMID 26940869, PMID 29217585, PMID 29471013, PMID 29698683, PMID 29724725, PMID 30242316, PMID 30305348, PMID 30359135, PMID 30395155, PMID 30643254, PMID 31678768, PMID 32179179, PMID 33613286, PMID 33962592, PMID 34905388, PMID 36529152, PMID 37315579, PMID 37410476, PMID 39020518, PMID 40845854, PMID 41112510, PMID 41120904
R01CA276684 (1)